Loading organizations...
§ Private Profile · Princeton, NJ, USA
Biopharmaceutical company developing optimized combination cancer therapy for acute myeloid leukemia and other oncology indications.
Celator Pharmaceuticals is a clinical-stage biopharmaceutical company developing combination cancer therapies using its proprietary CombiPlex technology platform, operating with dual headquarters in Ewing, New Jersey, and Vancouver, British Columbia. The enterprise focuses on optimizing drug combinations that integrate traditional chemotherapies with molecularly targeted agents to improve anti-cancer efficacy across various oncology indications, including acute myeloid leukemia and colorectal cancer. Prior to its public market debut on the Nasdaq exchange, the company secured a $32.5 million private placement financing round led by Valence Life Sciences in April 2013. Following successful Phase 3 clinical trials that demonstrated extended patient survival for its lead product candidate, the business was acquired by Jazz Pharmaceuticals in 2016 for a total valuation of $1.5 billion. Celator Pharmaceuticals was originally founded in 1999 by research scientists Lawrence Mayer and Marcel Bally.
Celator Pharmaceuticals has raised $118.1M across 7 funding rounds.
Celator Pharmaceuticals has raised $118.1M in total across 7 funding rounds.
Celator Pharmaceuticals has raised $118.1M across 7 funding rounds. Most recently, it raised $32.5M Other Equity in April 2013.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 30, 2013 | $32.5M Venture Round | Scott Morenstein | — | Announced |
| Dec 30, 2011 | $2.6M Venture Round | — | Domain Associates, GrowthWorks, Quaker Partners, The Leukemia & Lymphoma Society, Ventures West | Announced |
| Aug 1, 2010 | $20M Series D | Alex Zisson | Domain Associates, BDC Capital, GrowthWorks, Quaker Partners, TL Ventures, Ventures West | Announced |
| Jul 1, 2008 | $23M Series C | — | Domain Associates | Announced |
| Aug 2, 2007 | $10M Venture Round | — | BDC Capital, Domain Associates, GrowthWorks, Hearthstone Investments, Quaker Partners, TL Ventures, Ventures West | Announced |
| Aug 1, 2007 | $10M Series C | — | Domain Associates, BDC Capital, GrowthWorks, Hearthstone Investments, Quaker Partners, TL Ventures, Ventures West | Announced |
| May 1, 2005 | $20M Series B | — | Domain Associates | Announced |
Celator Pharmaceuticals has raised $118.1M in total across 7 funding rounds.
Celator Pharmaceuticals's investors include Scott Morenstein, Domain Associates, GrowthWorks, Quaker Partners, The Leukemia & Lymphoma Society, Ventures West, Alex Zisson, BDC Capital, TL Ventures, Hearthstone Investments.
Celator Pharmaceuticals is a biopharmaceutical company, not a technology company in the software or tech startup sense, focused on developing cancer therapies using its proprietary CombiPlex drug ratio technology platform.[1][2][3] This platform enables optimized combination therapies targeting cancer cells more effectively, with lead products like VYXEOS (CPX-351), a nano-scale liposomal formulation of cytarabine:daunorubicin for acute myeloid leukemia (AML), and CPX-1 for colorectal cancer.[1][3][4] It serves oncology patients with high unmet needs, solving the problem of suboptimal drug combinations in traditional chemotherapy by delivering precise ratios for enhanced efficacy.[2][3] The company raised about $89.7 million from investors including Jazz Pharmaceuticals, Hercules Capital, and BDC Venture Capital before being acquired.[1][5]
Founded in 1999 and headquartered in Ewing, New Jersey, Celator advanced to clinical-stage development, with VYXEOS showing statistically significant survival improvements in high-risk AML trials and earning FDA Breakthrough Therapy designation.[3][4] In 2016, Jazz Pharmaceuticals acquired it for $30.25 per share, integrating it as a subsidiary to leverage Jazz's hematology/oncology expertise.[3][4][5]
Celator Pharmaceuticals was founded in 1999, originally as Celator Technologies, Inc., and renamed in January 2005.[1][3] Based initially in Princeton, New Jersey (later Ewing), with operations in Vancouver, B.C., it emerged from research into nanotechnology and drug delivery for oncology.[1][4][7] Key early leaders included CEO Scott Jackson, who highlighted the company's dedication to differentiated therapies, and board members like Michael R. Dougherty (Chairman from 2014), with decades in biopharma commercialization of oncology drugs like Hycamtin and Erbitux, and Nicole Vitullo from Domain Associates.[4][7]
The idea stemmed from advancing CombiPlex, a platform for rational combination therapy design, leading to pivotal moments like Phase 3 trials for VYXEOS (CPX-351) in AML, which demonstrated superior overall survival.[2][3][4] Early traction included investor funding from firms like BDC Venture Capital and preclinical work on CPX-8, culminating in the 2016 acquisition by Jazz Pharmaceuticals after positive trial data.[1][4][5]
Celator stood out in oncology biopharma through these key strengths:
Celator rode the wave of nanotechnology in drug delivery and precision combination therapies, trends amplifying efficacy in oncology amid rising cancer prevalence and chemotherapy limitations.[1][3] Timing was ideal in the mid-2010s, with FDA fast-tracking (Breakthrough designation for VYXEOS) and investor interest in biotech innovation, fueled by market forces like orphan drug incentives for AML.[4] It influenced the ecosystem by validating liposomal tech for combos, paving the way for Jazz's expanded hematology portfolio and broader adoption of ratio-matched therapies in cancer treatment.[4][5]
Post-2016 acquisition, Celator's assets like VYXEOS have integrated into Jazz Pharmaceuticals, gaining regulatory approval (Vyxeos launched for AML) and generating revenue through Jazz's global infrastructure.[3][4][5] Next steps likely involve label expansions, international growth, and pipeline advancements from CPX-1/CPX-8, shaped by trends in personalized oncology and nanoparticle delivery.[3][4] Its influence endures as a benchmark for tech-enabled biopharma M&A, diversifying Jazz's offerings and underscoring CombiPlex's role in tackling unmet cancer needs—echoing its origins in innovative therapy design.[1][4]